ADPT ▲ +1.2% - Adaptive Biotechnologies Corporation $ADPT - Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® Adaptive Biotechnologies rose 1.2% following an announcement that its clonoSEQ® test received strengthened support in updated National Comprehensive Cancer Network (NCCN) guidelines for multiple myeloma, with expanded recommendations for minimal residual disease (MRD) testing. The guideline update represents clinical validation of the company's core diagnostic product and could broaden its use in myeloma treatment monitoring. 17-SEP-2026 08:00 AM ET